Clinical trials
catalyst calendar across sponsors →Studies where MXCT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 13 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, +8 more) · FINRA short interest 1.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal MesotheliomaNCT03608618Incidence and severity of adverse events as assessed by CTCAE v.5.0Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor shift in focus | Biological: MCY-M11 · Drug: Cyclophosphamide | Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma | 14 | 2021-02-11actual | 2021-09-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19